Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

Completed · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Hypertension

In brief

This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.

Key facts

Study ID

NCT00147199

Run by

United Therapeutics

People needed

235

Starts

2005-06-01

Expected to finish

2007-10-01

Last updated by the study team

2024-01-02

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinically stable, pulmonary arterial hypertension diagnosed as either idiopathic or familial PAH, collagen vascular disease associated PAH, HIV PAH, or PAH induced by anorexigens, New York Heart Association (NYHA) Class III or Class IV.
• Been on a stable dose of 125 mg twice daily (bid) of bosentan OR any stable dose of sildenafil for at least three months prior to study start
• An unencouraged six minute walk test (6MWT) of between 200 and 450 meters at screening
• Cardiac catheterization within the past 13 months consistent with PAH, specifically mean pulmonary artery pressure (PAPm) ≥25 mmHg (at rest), pulmonary capillary wedge pressure (PCWP) (or left ventricular end diastolic pressure) ≤15 mmHg, and pulmonary vascular resistance (PVR) >3 mmHg/L/min
• Within the past 12 months, patients must have had a chest radiograph consistent with the diagnosis of PAH
• Willing and able to follow all study procedures

You may not qualify if…

• Considering pregnancy, are pregnant and/or lactating
• PAH due to conditions other than noted in the above inclusion criteria.
• Have had any change in or discontinued any PAH medication within the last three months, including but not limited to endothelin receptor antagonist (ERA), or calcium channel blockers (CCB) (with the exception of anticoagulants)
• Have received any prostanoid within the 30 days before screening or are scheduled to receive any during the course of the study
• Have received any investigational medication within 30 days prior to the start of this study or are scheduled to receive another investigational drug during the course of this study
• Have a known intolerance to any drug, especially to treprostinil sodium or prostanoids
• Have an increased risk of hemorrhage
• Have a new type of chronic therapy (e.g., a different category of vasodilator, diuretic) for PAH added within the last month, except anticoagulants
• Have any musculoskeletal disease or any other disease that would limit ambulation.

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• University of Arizona — Tucson, Arizona, United States
• UCSD Medical center — La Jolla, California, United States
• UCLA Medical Center — Torrance, California, United States
• University of Colorado — Aurora, Colorado, United States
• Orlando Heart Center — Orlando, Florida, United States
• Kansas University Medical Center — Kansas City, Kansas, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Bethe Israel Medical Center — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Allegheny General Hospital — Pittsburgh, Pennsylvania, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• UTSW Medical Center — Dallas, Texas, United States
• Universitatsklinikfur Innere Medizin II — Wein, State of Vienna, Austria
• Medical University Graz — Graz, Austria
• Universite Libre de Bruxelles — Brussels, Belgium
• University Hospital Gasthuisburg — Leuven, Belgium
• Hospital Antoine Beclere — Paris, France
• Univesitatsklinikum Giessen und Marburg GmbH — Geißen, Germany
• Pulmonary Hypertension Unit — Dublin, Ireland
• Rambam Medical Center — Haifa, Israel
• The Pulmonary Institute — Jerusalem, Israel
• The Pulmonary Institute — Petach Tikvah 49100, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.